Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Day One Biopharmaceuticals
Day One Biopharmaceuticals
(DAWN)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
No data
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Tovorafenib
neoplasms
,
carcinoma
,
colorectal neoplasms
,
pancreatic neoplasms
,
non-small-cell lung carcinoma
,
urinary bladder neoplasms
,
melanoma
,
adenocarcinoma
,
papillary thyroid cancer
,
astrocytoma
,
acinar cell carcinoma
,
mutation rate
,
craniopharyngioma
,
adamantinoma
,
glioma
Paxalisib
recurrence
,
brain neoplasms
,
neoplasms
PIMASERTIB
neoplasms
,
carcinoma
,
colorectal neoplasms
,
pancreatic neoplasms
,
non-small-cell lung carcinoma
,
urinary bladder neoplasms
,
melanoma
,
adenocarcinoma
,
papillary thyroid cancer
,
astrocytoma
,
acinar cell carcinoma
,
mutation rate
,
recurrence
,
brain neoplasms
MLN-2480
glioma
Arm1
neoplasms
,
carcinoma
,
colorectal neoplasms
,
pancreatic neoplasms
,
non-small-cell lung carcinoma
,
urinary bladder neoplasms
,
melanoma
,
adenocarcinoma
,
papillary thyroid cancer
,
astrocytoma
,
acinar cell carcinoma
,
mutation rate
,
glioma
Arm2
neoplasms
,
carcinoma
,
colorectal neoplasms
,
pancreatic neoplasms
,
non-small-cell lung carcinoma
,
urinary bladder neoplasms
,
melanoma
,
adenocarcinoma
,
papillary thyroid cancer
,
astrocytoma
,
acinar cell carcinoma
,
mutation rate
,
glioma
MLN2480
glioma
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use